Enhancement of insulin-like growth factor I activity by novel antisera: potential structure/function interactions

Area of Science:

• Endocrinology
• Molecular Biology
• Immunology

Background:

• Insulin-like growth factor I (IGF-I) is crucial for growth, cell proliferation, differentiation, and survival.
• IGF-I activity is modulated by IGF-binding proteins (IGFBPs), which typically inhibit but sometimes potentiate its action.
• The mechanism by which some IGFBPs enhance IGF-I action remains unclear.

Purpose of the Study:

• To investigate a novel anti-human (h) IGF-I antiserum that enhances IGF-I activity in vivo.
• To explore the potential of this antiserum as a model for understanding enhancing IGFBP actions.
• To determine the epitope recognized by the enhancing antiserum and its functional implications.

Main Methods:

• In vitro assays measuring cell proliferation of bovine fibroblasts.
• Epitope scanning using overlapping octamer and hexamer peptides of IGF-I.
• In vivo studies using antibodies raised against a specific IGF-I peptide sequence.

Main Results:

• The anti-IGF-I antiserum enhanced IGF-I activity both in vivo and in vitro.
• Epitope mapping identified a linear region (residues Ser33 to Cys47) in the C-terminal/A domain recognized by the enhancing antiserum.
• This recognized region is distinct from the type 1 receptor-binding site, suggesting modulation of receptor interaction.

Conclusions:

• The enhancing anti-IGF-I antiserum provides a valuable model for studying IGF-I potentiation mechanisms.
• The identified epitope is critical for the antibody-mediated enhancement of IGF-I activity.
• This potentiating antiserum demonstrates therapeutic potential for conditions requiring cell repair or counteracting catabolism.